Table 1:
Structure-based vaccinology for human viruses
Virus | Structural Modification | Outcome | Ref |
---|---|---|---|
RSV | Identification of pre-fusion F protein structure | Allows vaccination with pre-fusion F-containing neutralizing epitopes | [105] |
Pre-fusion F stabilization | Highly immunogenic responses in vaccines | [106–108] | |
Epitope focused vaccine design | Proof-of-concept study developing an RSV vaccine for neutralizing epitopes of interest | [109] | |
SARS-CoV-2 | SARS-CoV-2 spike stabilization | Highly immunogenic vaccines with the S2P and HexaPro stabilizations | [26] |
SARS-CoV | Identification of SARS-CoV prefusion spike structure | Revealed new epitopes for vaccine design | [34, 110, 111] |
MERS-CoV | Identification of MERS-CoV prefusion spike structure | Highly immunogenic epitopes for vaccine development | [112, 113] |
HIV-1 | Stabilization of HIV-1 envelope protein | Generation of BG-SOSIP trimer immunogens capable of eliciting neutralizing antibodies | [27, 114–116] |
Structure of pre-fusion envelope | Atomic resolution of pre-fusion spike immunogens | [117, 118] | |
Engineered HIV-1 immunogens | Structural design of germline targeting immunogens | [53, 54, 119, 120] | |
Structural guided nanoparticle design | Structure based nanoparticle formulations are highly immunogenic for multiple viruses | [38, 121–123] |